Picture of rolled up £5 note

Open Access research that shapes economic thinking...

Strathprints makes available scholarly Open Access content by the Fraser of Allander Institute (FAI), a leading independent economic research unit focused on the Scottish economy and based within the Department of Economics. The FAI focuses on research exploring economics and its role within sustainable growth policy, fiscal analysis, energy and climate change, labour market trends, inclusive growth and wellbeing.

The open content by FAI made available by Strathprints also includes an archive of over 40 years of papers and commentaries published in the Fraser of Allander Economic Commentary, formerly known as the Quarterly Economic Commentary. Founded in 1975, "the Commentary" is the leading publication on the Scottish economy and offers authoritative and independent analysis of the key issues of the day.

Explore Open Access research by FAI or the Department of Economics - or read papers from the Commentary archive [1975-2006] and [2007-2018]. Or explore all of Strathclyde's Open Access research...

Pharmacotherapy to improve outcomes in infrainguinal bypass graft surgery : a review of current treatment strategies

Jackson, Andrew J. and Coats, Paul and Orr, Douglas J. and Teenan, R. Paul and Wadsworth, Roger M. (2010) Pharmacotherapy to improve outcomes in infrainguinal bypass graft surgery : a review of current treatment strategies. Annals of Vascular Surgery, 24 (4). pp. 562-572. ISSN 0890-5096

Full text not available in this repository. Request a copy from the Strathclyde author

Abstract

A total of 12,000 infrainguinal bypass grafts are performed annually in the United Kingdom, with outcomes suboptimal: 20% of above-knee vein grafts require intervention by 3 years. Transatlantic Inter-Society Consensus (TASC) guidelines exist on pharmacological management of peripheral vascular disease patients, however, little is recommended regarding optimum pharmacological management following revascularization to improve graft patency. The current recommendation is that all patients are on an antiplatelet agent following bypass grafting, the only intervention with significant evidence supporting use. This article will review pharmacological strategies aimed at improving the survival of infrainguinal vein grafts and the current evidence base for their use.